Myriad Genetics Corp (MYGN) - Prakiraan wutah bathi saben saham kanggo taun ngarep

Myriad Genetics (MYGN) - logo korporat

Myriad Genetics, Inc. (MYGN) relies on an ethical approach and a strong scientific foundation that ensures personnel stability. Structural growth in cancer diagnostics shields revenues from macroeconomic shocks. Shifting analyst expectations for EPS growth in year n+1 visualize this vector, where 2.60 captures the current state of the parameter. A unique array of genetic data, guaranteeing benchmark test accuracy, remains the foundation of success.

Myriad Genetics Inc (MYGN): Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep saka 04.07.2022 nganti 15.11.2026

MYGN (Myriad Genetics Inc): rincian analitis lan laporan miturut indikator

Analisis komprehensif perusahaan:Myriad Genetics Inc
Barang utama Myriad Genetics

Myriad Genetics, Inc. (MYGN) maintains a strong position due to the critical importance of genetic testing, which ensures predictable cash flows. This earnings per share growth forecast with a value of 2.60 aggregates analyst consensus expectations, measuring the balance between institutional demand and macroeconomic risks to determine the business's long-term return potential.